Managing the mild IBD patient

Dr AB Hawthorne
Consultant Gastroenterologist
University Hospital of Wales
Cardiff





Disclosures


Dr AB Hawthorne has received honoraria from Takeda UK Ltd, Janssen Ltd, and Ferring Ltd for speaking at, or chairing educational meetings, since Jan 2017


What is mild IBD??

- · Not causing bad symptoms
- · Not needing much therapy
- · Limited extent

How common is mild UC??


UC 25%* never 5-ASA 40%* never oral steroids






Rungoe C, et al. Gut 2014;63:1607

Literature Review: 17-33% no relapses over 10 yrs 47-60% no steroids




UC - IBSEN cohort diagnosed 1990-94





How common is mild Crohn's??

Crohn's 35%* never oral steroids



Rungoe C, et al. Gut 2014;63:1607





Solberg 2007; 5:1430

^{*} Approximate values

How common is mild Crohn's??

Crohn's-Tertiary cohort from Paris 15 yr FU Mild-Mod 279 (46.5%) (<3 yrs active disease; <1 operation; no CDrelated mortality)


Quiescent

Factors associated with mild-mod course (MV analysis)

- Disease duration
- Rectal involvement
- Never-smoker
- Higher educational level
- Olderage

5-ASA or no drugs

Note: perianal disease not significant factor



Cosnes Gut 2012;61:1140

What is mild IBD??

- Not causing bad symptoms
- Not needing much therapy
- Limited extent

- Quiescent after index flare
- Quiescent after surgery / intensive medical therapy
- "Burnt out" colitis


- Misdiagnosis
- Danger of overtreatment
- Loss to follow-up
 - Recognition of subclinical inflammation/change in extent
 - Need for cancer surveillance
- Impact of disease stigma on QOL and achievements
- Health economics and resource planning
- Understanding aetiology

Misdiagnosis – it isn't IBD at all!

- diverticular colitis
- mild self-limiting colitis (infective/drugs)
- a few aphthous ulcers in small bowel

Danger of overtreatment

Edward Louis:- "The currently available biologics are able to put a subset of patients in longstanding clinical and endoscopic remission, thereby mimicking what can be achieved with "curative" surgery"




Cohorts stopping anti-TNF:- 40-50% relapse over 2 yrs (vs 10-15% if continue). 50-90% are retreated successfully

Louis IBD 2018:24:725

Long-term follow-up of STORI cohort:-

- only 21.6% are free of biologics/surgical resection/complex perianal disease
- BUT if biologics are restarted only 20% have subsequent major complications

Reenaers CGH 2018;16:234



Danger of overtreatment

Other drugs

Diet and Lifestyle advice

Loss to follow-up

Does it matter? YES!

Missing subclinical disease activity:

Adelaide: 246 UC patients:-

Clinical remission 61%

Endoscopic " 35% Bryant JGH 2018;33:599

Histological " 16%

- Colon cancer surveillance
- Change in disease extent

- Treat to Target

Review colonoscopy with segmental biopsies important

- Extent
- Inflammation
- Dysplasia

Impact of disease stigma on QOL and achievements

· Health economics and resource planning


Prevalence of IBD in UK

Hamilton Gut 2018;67(S1):A67

Jones JCC 2019;13:S082

Lothian 0.78% (CD 0.28%, UC .43%)

Devon 0.8% (CD 0.31%, UC 0.45%)




Zuo Frontiers in Microbiology 2018;9:247

Follow-up for mild / quiescent IBD

Relentless pressure to improve "efficiency" of IBD services:



Follow-up for mild / quiescent IBD



- Educate (IBD team/patient/GP)
- Easy access back into service
- Monitor/audit

Summary

- Careful diagnosis and prognosis
- Don't overtreat
- Don't be afraid to stop treatment
- Appropriate remote monitoring
- More research into long-standing quiescent disease